文献速递脊柱关节炎

弥散加权成像可敏感反映附着点炎相关关节炎生物制剂治疗反应

Diffusion-weighted imaging is a sensitive biomarker of response to biologic therapy in enthesitis-related arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

结果显示,达到影像学应答者治疗后ADC和nADC下降幅度大于无应答者(ADC P<0.01),ADC预测影像学应答的AUC为0.97,nADC为0.82;临床应答方面ADC与nADC的预测敏感性特异性中等。结论认为DWI测量可反映TNF抑制剂治疗反应,ADC/nADC有望作为骶髂关节炎的生物标志物。

要点

  • ERA青少年TNF抑制剂治疗后,影像学应答者ADC下降幅度显著大于无应答者(P<0.01)。
  • ADC预测影像学应答的AUC为0.97,nADC为0.82,敏感性和特异性高。
  • ADC/nADC对临床应答的预测敏感性、特异性中等,AUC分别为0.67和0.78。

核心结论

  • DWI测量可反映ERA伴骶髂关节炎患者对TNF抑制剂的影像学应答,也可能反映临床应答。
  • DWI比视觉评分更客观,并具有自动化潜力,ADC/nADC可作为临床和临床试验中骶髂关节炎的生物标志物。

研究设计与样本

  • 由两名放射科医生采用加拿大脊柱关节炎研究联盟(SPARCC)系统进行视觉评分,并测量骶髂关节表观弥散系数(ADC)和标准化ADC(nADC)。
  • 临床应答定义为医生总体评估改善≥30%,影像学应答定义为SPARCC评分降低≥2.5分。
  • 采用Mann-Whitney-Wilcoxon检验比较应答者与无应答者的ADC和nADC变化。

主要发现

  • 影像学应答者治疗后ADC下降幅度大于无应答者(P<0.01),nADC下降幅度组间差异P=0.055。
  • 临床应答者治疗后ADC下降幅度与无应答者差异P=0.33,nADC下降幅度差异P=0.089。
  • ADC预测影像学应答的AUC为0.97,nADC为0.82;预测临床应答的AUC分别为0.67和0.78。

关键数值与推荐

  • 临床应答定义为医生总体评估改善≥30%。
  • 影像学应答定义为SPARCC评分降低≥2.5分。
  • 影像学应答预测:ADC的AUC为0.97,nADC的AUC为0.82。
  • 临床应答预测:ADC的AUC为0.67,nADC的AUC为0.78。

临床怎么用

  • 在ERA伴骶髂关节炎患者中,可采用DWI测量的ADC/nADC作为TNF抑制剂治疗反应的客观影像学标志物。
  • ADC/nADC对影像学应答的预测敏感性和特异性高,对临床应答的预测敏感性、特异性中等,临床解读需结合临床评估。

局限性

  • 临床应答预测的组间ADC变化差异无统计学意义(P=0.33),nADC差异亦未达显著(P=0.089)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim was to evaluate diffusion-weighted imaging (DWI) as a tool for measuring treatment response in adolescents with enthesitis-related arthropathy (ERA). METHODS: Twenty-two adolescents with ERA underwent routine MRI and DWI before and after TNF inhibitor therapy. Each patient's images were visually scored by two radiologists using the Spondyloarthritis Research Consortium of Canada system, and sacroiliac joint apparent diffusion coefficient (ADC) and normalized ADC (nADC) were measured for each patient. Therapeutic clinical response was defined as an improvement of ⩾ 30% physician global assessment and radiological response defined as ⩾ 2.5-point reduction in Spondyloarthritis Research Consortium of Canada score. We compared ADC and nADC changes in responders and non-responders using the Mann-Whitney-Wilcoxon test. RESULTS: For both radiological and clinical definitions of response, reductions in ADC and nADC after treatment were greater in responders than in non-responders (for radiological response: ADC: P < 0.01; nADC: P = 0.055; for clinical response: ADC: P = 0.33; nADC: P = 0.089). ADC and nADC could predict radiological response with a high level of sensitivity and specificity and were moderately sensitive and specific predictors of clinical response (the area under the receiver operating characteristic curves were as follows: ADC: 0.97, nADC: 0.82 for radiological response; and ADC: 0.67, nADC: 0.78 for clinical response). CONCLUSION: DWI measurements reflect the response to TNF inhibitor treatment in ERA patients with sacroiliitis as defined using radiological criteria and may also reflect clinical response. DWI is more objective than visual scoring and has the potential to be automated. ADC/nADC could be used as biomarkers of sacroiliitis in the clinic and in clinical trials.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. J P Bray T, Vendhan K, Ambrose N, et al. Diffusion-weighted imaging is a sensitive biomarker of response to biologic therapy in enthesitis-related arthritis. Rheumatology (Oxford). 2017. PMID: 27994095. doi:10.1093/rheumatology/kew429

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。